Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections. It has developed eravacycline using its chemistry technology. The Company's TP-271 is a fully synthetic spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens. It also develops TP-6076 for multidrug-resistant Gram- negative infections.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TTPH
  • CUSIP:
Key Metrics:
  • Previous Close: $5.20
  • 50 Day Moving Average: $4.43
  • 200 Day Moving Average: $4.05
  • 52-Week Range: $3.11 - $6.28
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.18
  • P/E Growth: -0.02
  • Market Cap: $191.90M
  • Outstanding Shares: 36,904,000
  • Beta: 2.66
Profitability:
  • Net Margins: -1,120.67%
  • Return on Equity: -39.95%
  • Return on Assets: -37.74%
Debt:
  • Current Ratio: 15.54%
  • Quick Ratio: 15.54%
Additional Links:
Companies Related to Tetraphase Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (?)
Ratings Breakdown: 4 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $5.67 (8.97% upside)

Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Show:
DateFirmActionRatingPrice TargetDetails
11/4/2016BMO Capital MarketsReiterated RatingHold$6.00View Rating Details
11/4/2016WedbushReiterated RatingNeutral$4.00View Rating Details
5/16/2016GabelliReiterated RatingNeutralView Rating Details
5/14/2016Needham & Company LLCReiterated RatingHoldView Rating Details
11/19/2015SunTrust Banks, Inc.UpgradeNeutral -> Buy$12.00 -> $21.00View Rating Details
9/9/2015GuggenheimLower Price TargetBuy$60.00 -> $20.00View Rating Details
9/9/2015Robert W. BairdDowngradeOutperform -> Neutral$41.00 -> $10.00View Rating Details
9/9/2015Cantor FitzgeraldDowngradeBuy -> Hold$50.00 -> $11.00View Rating Details
9/9/2015NomuraDowngradeBuy -> Neutral$54.00 -> $10.00View Rating Details
9/9/2015Stifel NicolausDowngradeBuy -> Hold$57.00View Rating Details
9/9/2015Brean CapitalDowngradeBuy -> HoldView Rating Details
9/9/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
11/3/2016($0.50)($0.58)$1.58 million$0.90 millionViewN/AView Earnings Details
8/4/2016Q2($0.46)($0.47)$2.05 million$1.20 millionViewN/AView Earnings Details
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details
3/5/2015($0.54)($0.69)ViewN/AView Earnings Details
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details
3/6/2014($0.46)($0.49)ViewN/AView Earnings Details
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Current Year EPS Consensus Estimate: $-2.12 EPS
Next Year EPS Consensus Estimate: $-2.39 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.46)($0.41)($0.44)
Q2 20162($0.48)($0.44)($0.46)
Q3 20162($0.49)($0.47)($0.48)
Q4 20162($0.56)($0.47)($0.52)
Q1 20172($0.56)($0.55)($0.56)
Q2 20171($0.58)($0.58)($0.58)
Q3 20172($0.59)($0.58)($0.59)
Q4 20171($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 55.63%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.00View SEC Filing  
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.00View SEC Filing  
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.00View SEC Filing  
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.54View SEC Filing  
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.50View SEC Filing  
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View SEC Filing  
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View SEC Filing  
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View SEC Filing  
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View SEC Filing  
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateHeadline
News IconEquity Focus: Zeroing in on Shares of Tetraphase Pharmaceuticals Inc (TTPH) - Rives Journal (NASDAQ:TTPH)
rivesjournal.com - February 22 at 9:33 PM
News IconShares Worth Watching: Tetraphase Pharmaceuticals, Inc ... - Rockville Register (NASDAQ:TTPH)
rockvilleregister.com - February 22 at 9:33 PM
News IconMomentum & Technical Update on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Midway Monitor (NASDAQ:TTPH)
midwaymonitor.com - February 22 at 9:33 PM
News IconBrokerage Analyst Recommendation Focus on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) StoneCastle ... - Rives Journal (NASDAQ:TTPH)
rivesjournal.com - February 21 at 4:33 PM
News IconInvesting Focus: Indicators in View on Shares of Tetraphase Pharmaceuticals Inc (TTPH) - Davidson Register (NASDAQ:TTPH)
davidsonregister.com - February 21 at 4:33 PM
News IconIs The Sell-Side Predicting That Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Will Move Higher? - Winfield Review (NASDAQ:TTPH)
winfieldreview.com - February 17 at 6:54 PM
News IconWatching the Charts on Tetraphase Pharmaceuticals Inc (TTPH) - Benton Bulletin (NASDAQ:TTPH)
bentonbulletin.com - February 17 at 6:54 PM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Quarterly EPS At $-0.615 - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - February 17 at 6:54 PM
News IconThe Charts For Tetraphase Pharmaceuticals, Inc. (TTPH) Is Speaking Volumes Today - NY Stock News (NASDAQ:TTPH)
nystocknews.com - February 17 at 6:54 PM
thestreet.com logoFirst Week Of August 18th Options Trading For Tetraphase Pharmaceuticals (TTPH) (NASDAQ:TTPH)
www.thestreet.com - February 15 at 6:40 AM
News IconChart Indicators in Focus for Tetraphase Pharmaceuticals Inc (TTPH) - Baldwin Journal (NASDAQ:TTPH)
baldwinjournal.com - February 14 at 6:41 AM
investopedia.com logoTetraphase Says Antibiotic Has Strong Sales Prospects (NASDAQ:TTPH)
www.investopedia.com - February 14 at 6:41 AM
News IconShares to Watch: Indicator Update on Tetraphase Pharmaceuticals Inc (TTPH) - Rives Journal (NASDAQ:TTPH)
rivesjournal.com - February 10 at 6:15 AM
News IconMarket Center: Following Shares of Tetraphase Pharmaceuticals Inc (TTPH) - Providence Standard (NASDAQ:TTPH)
providencestandard.com - February 9 at 6:20 AM
nasdaq.com logoUPDATE 1-Tetraphase antibiotic may reach up to $700 mln in annual sales: CEO - Nasdaq (NASDAQ:TTPH)
www.nasdaq.com - February 9 at 6:20 AM
finance.yahoo.com logoTetraphase antibiotic could reach $700 mln in annual sales -CEO (NASDAQ:TTPH)
finance.yahoo.com - February 9 at 6:20 AM
finance.yahoo.com logoTetraphase antibiotic may reach up to $700 mln in annual sales: CEO (NASDAQ:TTPH)
finance.yahoo.com - February 9 at 6:20 AM
biz.yahoo.com logoTETRAPHASE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:TTPH)
biz.yahoo.com - February 8 at 8:07 AM
News IconEarnings According to Analysts for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)? - Aiken Advocate (NASDAQ:TTPH)
aikenadvocate.com - February 2 at 6:12 AM
News IconEarnings in Full Force, Analysts Take Aim at Tetraphase ... - Wall Street Beacon (NASDAQ:TTPH)
wsbeacon.com - January 28 at 7:15 AM
News IconEarnings in Full Force, Analysts Take Aim at Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Wall Street Beacon (NASDAQ:TTPH)
wsbeacon.com - January 28 at 7:15 AM
News IconUpdate on Valuation Formula's For Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - The Tribune (NASDAQ:TTPH)
lakecitytribune.com - January 24 at 8:05 AM
News IconTrading Scope: Following Levels on Shares of Tetraphase Pharmaceuticals Inc (TTPH) - Sherwood Daily (NASDAQ:TTPH)
sherwooddaily.com - January 22 at 8:06 PM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Daily Sentiment Score At 0.346 - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - January 21 at 8:09 PM
News IconWhat are the Levels Indicating for This Stock: Tetraphase Pharmaceuticals Inc (TTPH) - Sherwood Daily (NASDAQ:TTPH)
sherwooddaily.com - January 20 at 7:20 AM
News IconTetraphase Pharmaceuticals Inc TTPH Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:TTPH)
www.bioportfolio.com - January 20 at 7:20 AM
News IconGearing Up For a Bull Run? Analysts Weigh in on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Wall Street Beacon (NASDAQ:TTPH)
wsbeacon.com - January 19 at 5:56 AM
News IconTechnical Watch on These Shares: Tetraphase Pharmaceuticals Inc (TTPH) - Rives Journal (NASDAQ:TTPH)
rivesjournal.com - January 19 at 5:56 AM
biz.yahoo.com logoTETRAPHASE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a (NASDAQ:TTPH)
biz.yahoo.com - January 18 at 3:26 AM
finance.yahoo.com logoTetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI (NASDAQ:TTPH)
finance.yahoo.com - January 17 at 10:33 AM
News IconWill The Needle Move For Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:TTPH)
wsbeacon.com - January 15 at 2:32 AM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Bearish Target At $14 - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - January 11 at 7:33 AM
News IconDaily Sentiment Score Of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) At 0.568 - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - January 8 at 6:16 AM
News IconDaily Sentiment Score Of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) At 0 - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - January 1 at 1:10 AM
News IconBearish Target Of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) At $14 - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - December 26 at 7:29 PM
us.rd.yahoo.com logo8:08 am Tetraphase Pharmaceuticals updates on eravacycline; co plans to submit a MAA to the EMA for IV eravacycline for the treatment of cIAI during 2h17 and plans to initiate IGNITE3 during 1Q17 (NASDAQ:TTPH)
us.rd.yahoo.com - December 20 at 4:58 PM
publicnow.com logoTetraphase Pharmaceuticals Provides Regulatory and Clinical Update for Eravacycline (NASDAQ:TTPH)
www.publicnow.com - December 20 at 4:58 PM
biz.yahoo.com logoTETRAPHASE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:TTPH)
biz.yahoo.com - December 20 at 4:58 PM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - December 18 at 3:26 AM
insidermonkey.com logoTetraphase Pharmaceuticals Inc (TTPH): Hedge Funds Are Snapping Up (NASDAQ:TTPH)
www.insidermonkey.com - December 17 at 5:04 AM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Quarterly EPS ... - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - December 16 at 6:08 AM
insidermonkey.com logoTetraphase Pharmaceuticals Inc (TTPH): Hedge Funds Are ... - Insider Monkey (blog) (NASDAQ:TTPH)
www.insidermonkey.com - December 16 at 6:08 AM
capitalcube.com logoETFs with exposure to Tetraphase Pharmaceuticals, Inc. : December 13, 2016 (NASDAQ:TTPH)
www.capitalcube.com - December 14 at 6:59 AM
News IconADX in View on Shares of Tetraphase Pharmaceuticals Inc (TTPH) - Yankee Analysts (NASDAQ:TTPH)
yankeeanalysts.com - December 11 at 8:28 AM
News IconTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Quarterly EPS Seen At $-0.615 - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - December 9 at 1:52 AM
News IconTrading Scope: Indicator Review for Tetraphase Pharmaceuticals Inc (TTPH) - Yankee Analysts (NASDAQ:TTPH)
yankeeanalysts.com - December 8 at 1:12 AM
News IconLevels in Review for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Marion Business Daily (NASDAQ:TTPH)
marionbusinessdaily.com - December 4 at 7:13 PM
News IconStock News Sentiment Of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) In Focus - Stock Observer (NASDAQ:TTPH)
www.thestockobserver.com - December 3 at 7:17 PM
News IconInvestor Circle: Watching the Numbers on Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Marion Business Daily (NASDAQ:TTPH)
marionbusinessdaily.com - November 28 at 8:30 AM
News IconTechnical Updates on Shares of Tetraphase Pharmaceuticals Inc (TTPH) - Yankee Analysts (NASDAQ:TTPH)
yankeeanalysts.com - November 28 at 8:30 AM

Social

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 1 year price objectives for Tetraphase Pharmaceuticals' shares. Their forecasts range from $4.00 to $7.00. On average, they expect Tetraphase Pharmaceuticals' share price to reach $5.67 in the next twelve months.

When will Tetraphase Pharmaceuticals announce their earnings?

Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (5.33%), State Street Corp (1.93%), Eventide Asset Management LLC (1.63%), Renaissance Technologies LLC (0.96%), Dimensional Fund Advisors LP (0.61%) and Numeric Investors LLC (0.49%). Company insiders that own Tetraphase Pharmaceuticals stock include David Charles Lubner, Guy Macdonald, John Craig Thompson, L Patrick Gage and Patrick Taylor Horn.

Who sold Tetraphase Pharmaceuticals stock? Who is selling Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Numeric Investors LLC and FMR LLC.

Who bought Tetraphase Pharmaceuticals stock? Who is buying Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Russell Investments Group Ltd., Cigna Investments Inc. New, A.R.T. Advisors LLC, GSA Capital Partners LLP, State Street Corp, Teton Advisors Inc. and Federated Investors Inc. PA.

How do I buy Tetraphase Pharmaceuticals stock?

Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Tetraphase Pharmaceuticals stock cost?

One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $5.20.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Earnings History Chart

Earnings by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Dividend History Chart

Dividend Payments by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Last Updated on 2/23/2017 by MarketBeat.com Staff